Routine thromboprophylaxis represents the current standard of care in the management of patients following total hip or knee replacement. Legacy agents used to address the issue of risk of venous thromboembolism present barriers to use, either by the need for monitoring and dose adjustment (warfarin) or the need for injection (low molecular weight heparins and fondaparinux), or pose a risk of u...

BACKGROUND Doppler ultrasound imaging is useful for management of venous thromboembolism associated with a subclavicular implantable central venous access system in patients receiving bevacizumab (Bev). We investigated the efficacy and safety of our anticoagulant regimen based on Doppler findings. METHODS Patients aged ≤75 years with metastatic colorectal cancer, no history of thromboembolism...

Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com 615 ABSTRACT Introduction: Venous thromboembolism is a burden on healthcare systems. The aim of this analysis was to project the long-term costs and outcomes for rivaroxaban compared to standard of care (enoxaparin/warfarin) in Portugal for the treatment and secondary prevention of venous thromboembolism. Material and Methods:...

INTRODUCTION Currently available anticoagulants have limitations for long term treatment of venous thromboembolism (VTE). OBJECTIVE A meta-analysis was performed to evaluate the efficacy and safety of new oral anticoagulants (NOACs) for extended treatment of VTE. METHODS PubMed, Cochrane Library, EMBASE, Web of Science and CINAHL databases were searched from January 01, 2001 through Februar...

The gold standard for secondary thromboprophylaxis in APS is long term anticoagulation with vitamin K antagonists (VKAs). Because of their widespread use and potential advantages directs oral anticoagulants (DOACs) over VKAs, they have been prescribed without definitive evidence safety efficacy this context. Recent specific randomized controlled trials (RCT) results from pivotal RCTs comparing ...